A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group.

The outbreak of coronavirus disease 2019 (COVID-19) has rapidly spread globally since being identified as a public health emergency of major international concern and has now been declared a pandemic by the World Health Organization (WHO). In December 2019, an outbreak of atypical pneumonia, known as COVID-19, was identified in Wuhan, China. The newly identified zoonotic coronavirus, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is characterized by rapid human-to-human transmission. Many cancer patients frequently visit the hospital for treatment and disease surveillance. They may be immunocompromised due to the underlying malignancy or anticancer therapy and are at higher risk of developing infections. Several factors increase the risk of infection, and cancer patients commonly have multiple risk factors. Cancer patients appear to have an estimated twofold increased risk of contracting SARS-CoV-2 than the general population. With the WHO declaring the novel coronavirus outbreak a pandemic, there is an urgent need to address the impact of such a pandemic on cancer patients. This include changes to resource allocation, clinical care, and the consent process during a pandemic. Currently and due to limited data, there are no international guidelines to address the management of cancer patients in any infectious pandemic. In this review, the potential challenges associated with managing cancer patients during the COVID-19 infection pandemic will be addressed, with suggestions of some practical approaches. This article is protected by copyright. All rights reserved.

The oncologist. 2020 Apr 03 [Epub ahead of print]

Humaid O Al-Shamsi, Waleed Alhazzani, Ahmad Alhuraiji, Eric A Coomes, Roy F Chemaly, Meshari Almuhanna, Robert Wolff, Ibrahim K Nuhad, Melvin L K Chua, Sebastien J Hotte, Brandon M Meyers, Tarek Elfiki, Giuseppe Curigliano, Cathy Eng, Axel Grothey, Conghua Xie

Medical Oncology Department, Alzahra Hospital Dubai, Dubai, United Arab Emirates., Department of Health Research Methods, Evidence, and Impact, Hamilton, Ontario, Canada., Department of Hematology, Kuwait Cancer Control Center, Kuwait., Division of Infectious Disease, Department of Medicine, University of Toronto, Toronto, Ontario, Canada., Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Min-Sheng General Hospital, Taoyuan City, Taiwan., Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA., Divisions of Radiation Oncology and Medical Sciences, National Cancer Center Singapore, Singapore., Department of Oncology, Juravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada., Windsor Regional Cancer Center, Windsor, Ontario, Canada., Department of Oncology and Hemato-Oncology University of Milan, Milan, Italy., Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA., West Cancer Center, University of Tennessee, Memphis, Tennessee, USA., Department of Radiation and Medical Oncology, Zhongnan Hospital of Wuhan University, Wuhan, People's Republic of China.